1. Market Research
  2. > Lung Cancer - Pipeline Review, H2 2013

Lung Cancer - Pipeline Review, H2 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 499 pages

Lung Cancer - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Lung Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Cancer. Lung Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lung Cancer.
- A review of the Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lung Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lung Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lung Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Lung Cancer - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
Introduction 7
Lung Cancer Overview 8
Therapeutics Development 9
Lung Cancer Therapeutics under Development by Companies 11
Lung Cancer Therapeutics under Investigation by Universities/Institutes 21
Late Stage Products 24
Mid Clinical Stage Products 25
Early Clinical Stage Products 26
Discovery and Pre-Clinical Stage Products 27
Lung Cancer Therapeutics - Products under Development by Companies 28
Lung Cancer Therapeutics - Products under Investigation by Universities/Institutes 38
Companies Involved in Lung Cancer Therapeutics Development 41
Lung Cancer - Therapeutics Assessment 131
Drug Profiles 138
Lung Cancer Therapeutics - Drug Profile Updates 389
Lung Cancer Therapeutics - Discontinued Products 457
Lung Cancer Therapeutics - Dormant Products 458
Inflammatory Bowel Disease - Product Development Milestones 467
Appendix 478



List of Tables

Number of Products Under Development for Lung Cancer, H2 2013 29
Products under Development for Lung Cancer - Comparative Analysis, H2 2013 30
Number of Products under Development by Companies, H2 2013 32
Number of Products under Development by Companies, H2 2013 (Contd..1) 33
Number of Products under Development by Companies, H2 2013 (Contd..2) 34
Number of Products under Development by Companies, H2 2013 (Contd..3) 35
Number of Products under Development by Companies, H2 2013 (Contd..4) 36
Number of Products under Development by Companies, H2 2013 (Contd..5) 37
Number of Products under Development by Companies, H2 2013 (Contd..6) 38
Number of Products under Development by Companies, H2 2013 (Contd..7) 39
Number of Products under Development by Companies, H2 2013 (Contd..8) 40
Number of Products under Investigation by Universities/Institutes, H2 2013 42
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..1) 43
Comparative Analysis by Late Stage Development, H2 2013 44
Comparative Analysis by Mid Clinical Stage Development, H2 2013 45
Comparative Analysis by Early Clinical Stage Development, H2 2013 46
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 47
Products under Development by Companies, H2 2013 48
Products under Development by Companies, H2 2013 (Contd..1) 49
Products under Development by Companies, H2 2013 (Contd..2) 50
Products under Development by Companies, H2 2013 (Contd..3) 51
Products under Development by Companies, H2 2013 (Contd..4) 52
Products under Development by Companies, H2 2013 (Contd..5) 53
Products under Development by Companies, H2 2013 (Contd..6) 54
Products under Development by Companies, H2 2013 (Contd..7) 55
Products under Development by Companies, H2 2013 (Contd..8) 56
Products under Development by Companies, H2 2013 (Contd..9) 57
Products under Investigation by Universities/Institutes, H2 2013 58
Products under Investigation by Universities/Institutes, H2 2013 (Contd..1) 59
Products under Investigation by Universities/Institutes, H2 2013 (Contd..2) 60
Boehringer Ingelheim GmbH, H2 2013 61
Kyowa Hakko Kirin Co., Ltd., H2 2013 62
Amgen Inc., H2 2013 63
Sanofi-Aventis, H2 2013 64
AstraZeneca PLC, H2 2013 65
Eli Lilly and Company, H2 2013 66
Viralytics Ltd., H2 2013 67
Seattle Genetics, Inc., H2 2013 68
Inovio Biomedical Corporation, H2 2013 69
Bavarian Nordic A/S, H2 2013 70
Gilead Sciences, Inc., H2 2013 71
Biotest AG, H2 2013 72
Merck and Co., Inc., H2 2013 73
AandG Pharmaceutical, Inc., H2 2013 74
ViaCord, H2 2013 75
Amorfix Life Sciences Ltd., H2 2013 76
Ipsen S.A., H2 2013 77
Aposense Ltd., H2 2013 78
Millennium Pharmaceuticals, Inc., H2 2013 79
Astellas Pharma Inc., H2 2013 80
CK Life Sciences Int'l., (Holdings) Inc., H2 2013 81
Daewoong Pharmaceutical Co., Ltd., H2 2013 82
Les Laboratoires Servier, H2 2013 83
Nippon Kayaku Co., Ltd., H2 2013 84
SuperGen, Inc., H2 2013 85
Taiho Pharmaceutical Co., Ltd., H2 2013 86
Santaris Pharma A/S, H2 2013 87
Menarini Group, H2 2013 88
AntiCancer, Inc., H2 2013 89
4SC AG, H2 2013 90
Momenta Pharmaceuticals, Inc., H2 2013 91
ValiRx Plc, H2 2013 92
IMMUNOMEDICS, INC, H2 2013 93
Ariad Pharmaceuticals, Inc., H2 2013 94
Lorus Therapeutics Inc, H2 2013 95
Bionomics Limited, H2 2013 96
Orchid Chemicals and Pharmaceuticals Ltd, H2 2013 97
Patrys Limited, H2 2013 98
ARQULE, INC, H2 2013 99
Cytokinetics, Inc, H2 2013 100
Telik, Inc., H2 2013 101
CytRx Corporation, H2 2013 102
Pharmacyclics, Inc., H2 2013 103
Dendreon Corporation, H2 2013 104
ProMetic Life Sciences Inc., H2 2013 105
Progen Pharmaceuticals Limited, H2 2013 106
Sareum Holdings plc, H2 2013 107
Microbio Co., Ltd., H2 2013 108
Rexahn Pharmaceuticals, Inc., H2 2013 109
Scancell Holdings Plc, H2 2013 110
Nanobiotix, H2 2013 111
Antisense Pharma GmbH, H2 2013 112
Chipscreen Biosciences Ltd, H2 2013 113
CIMAB S.A., H2 2013 114
Supratek Pharma Inc., H2 2013 115
Bionucleon Srl, H2 2013 116
Actis Biologics, Inc, H2 2013 117
Med Discovery SA, H2 2013 118
Hutchison MediPharma Limited, H2 2013 119
Alethia Biotherapeutics Inc., H2 2013 120
Ascenta Therapeutics, Inc., H2 2013 121
Gene Signal International SA., H2 2013 122
OncoMed Pharmaceuticals, Inc., H2 2013 123
Five Prime Therapeutics, Inc., H2 2013 124
Kalos Therapeutics, Inc., H2 2013 125
PanaGin Pharmaceuticals Inc., H2 2013 126
GP Pharm, S.A., H2 2013 127
Merrimack Pharmaceuticals, Inc., H2 2013 128
Deciphera Pharmaceuticals, LLC, H2 2013 129
BioCancell Therapeutics, Inc., H2 2013 130
Omnitura Therapeutics Inc., H2 2013 131
Pharminox Limited, H2 2013 132
Mirna Therapeutics, Inc., H2 2013 133
Transtech Pharma, Inc., H2 2013 134
Welichem Biotech Inc., H2 2013 135
NewLink Genetics Corporation, H2 2013 136
Cellceutix Corporation, H2 2013 137
PharmaMar, S.A., H2 2013 138
TVAX Biomedical, LLC, H2 2013 139
Biokine Therapeutics Ltd., H2 2013 140
Genelux Corporation, H2 2013 141
Viventia Biotechnologies Inc., H2 2013 142
Kuhnil Pharmaceutical Co., Ltd., H2 2013 143
Advanced Cancer Therapeutics, H2 2013 144
Sunshine Biopharma, Inc., H2 2013 145
ISU ABXIS Co.,Ltd., H2 2013 146
Bioo Therapeutics, H2 2013 147
Ensoltek Co., Ltd., H2 2013 148
Almac Discovery Ltd., H2 2013 149
RaQualia Pharma Inc., H2 2013 150
Assessment by Monotherapy Products, H2 2013 151
Assessment by Combination Products, H2 2013 152
Assessment by Stage and Route of Administration, H2 2013 154
Assessment by Stage and Molecule Type, H2 2013 157
Lung Cancer Therapeutics - Drug Profile Updates 409
Lung Cancer Therapeutics - Discontinued Products 477
Lung Cancer Therapeutics - Dormant Products 478
Lung Cancer Therapeutics - Dormant Products (Contd..1) 479
Lung Cancer Therapeutics - Dormant Products (Contd..2) 480
Lung Cancer Therapeutics - Dormant Products (Contd..3) 481
Lung Cancer Therapeutics - Dormant Products (Contd..4) 482
Lung Cancer Therapeutics - Dormant Products (Contd..5) 483
Lung Cancer Therapeutics - Dormant Products (Contd..6) 484
Lung Cancer Therapeutics - Dormant Products (Contd..7) 485
Lung Cancer Therapeutics - Dormant Products (Contd..8) 486



List of Figures

Number of Products under Development for Lung Cancer, H2 2013 29
Products under Development for Lung Cancer - Comparative Analysis, H2 2013 30
Products under Development by Companies, H2 2013 31
Products under Investigation by Universities/Institutes, H2 2013 41
Late Stage Products, H2 2013 44
Mid Clinical Stage Products, H2 2013 45
Early Clinical Stage Products, H2 2013 46
Discovery and Pre-Clinical Stage Products, H2 2013 47
Assessment by Monotherapy Products, H2 2013 151
Assessment by Combination Products, H2 2013 152
Assessment by Route of Administration, H2 2013 153
Assessment by Stage and Route of Administration, H2 2013 154
Assessment by Molecule Type, H2 2013 155
Assessment by Stage and Molecule Type, H2 2013 156



Companies Mentioned

Boehringer Ingelheim GmbH
Kyowa Hakko Kirin Co., Ltd.
Amgen Inc.
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
Viralytics Ltd.
Seattle Genetics, Inc.
Inovio Biomedical Corporation
Bavarian Nordic A/S
Gilead Sciences, Inc.
Biotest AG
Merck and Co., Inc.
AandG Pharmaceutical, Inc.
ViaCord
Amorfix Life Sciences Ltd.
Ipsen S.A.
Aposense Ltd.
Millennium Pharmaceuticals, Inc.
Astellas Pharma Inc.
CK Life Sciences Int'l., (Holdings) Inc.
Daewoong Pharmaceutical Co., Ltd.
Les Laboratoires Servier
Nippon Kayaku Co., Ltd.
SuperGen, Inc.
Taiho Pharmaceutical Co., Ltd.
Santaris Pharma A/S
Menarini Group
AntiCancer, Inc.
4SC AG
Momenta Pharmaceuticals, Inc.
ValiRx Plc
IMMUNOMEDICS, INC
Ariad Pharmaceuticals, Inc.
Lorus Therapeutics Inc
Bionomics Limited
Orchid Chemicals and Pharmaceuticals Ltd
Patrys Limited
ARQULE, INC
Cytokinetics, Inc
Telik, Inc.
CytRx Corporation
Pharmacyclics, Inc.
Dendreon Corporation
ProMetic Life Sciences Inc.
Progen Pharmaceuticals Limited
Sareum Holdings plc
Microbio Co., Ltd.
Rexahn Pharmaceuticals, Inc.
Scancell Holdings Plc
Nanobiotix
Antisense Pharma GmbH
Chipscreen Biosciences Ltd
CIMAB S.A.
Supratek Pharma Inc.
Bionucleon Srl
Actis Biologics, Inc
Med Discovery SA
Hutchison MediPharma Limited
Alethia Biotherapeutics Inc.
Ascenta Therapeutics, Inc.
Gene Signal International SA.
OncoMed Pharmaceuticals, Inc.
Five Prime Therapeutics, Inc.
Kalos Therapeutics, Inc.
PanaGin Pharmaceuticals Inc.
GP Pharm, S.A.
Merrimack Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, LLC
BioCancell Therapeutics, Inc.
Omnitura Therapeutics Inc.
Pharminox Limited
Mirna Therapeutics, Inc.
Transtech Pharma, Inc.
Welichem Biotech Inc.
NewLink Genetics Corporation
Cellceutix Corporation
PharmaMar, S.A.
TVAX Biomedical, LLC
Biokine Therapeutics Ltd.
Genelux Corporation
Viventia Biotechnologies Inc.
Kuhnil Pharmaceutical Co., Ltd.
Advanced Cancer Therapeutics
Sunshine Biopharma, Inc.
ISU ABXIS Co.,Ltd.
Bioo Therapeutics
Ensoltek Co., Ltd.
Almac Discovery Ltd.
RaQualia Pharma Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.